您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > URMC-099
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
URMC-099
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
URMC-099图片
CAS NO:1229582-33-5
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
5mg电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
URMC-099 是一种口服生物有效的混合谱系激酶 3 (MLK3) (IC50=14 nM) 抑制剂,具有优异的血脑屏障穿透性。
生物活性

URMC-099 is an orally bioavailable and potentmixed lineage kinasetype 3 (MLK3) (IC50=14 nM) inhibitor with with excellent blood-brain barrier penetration properties.

IC50& Target

LRRK2

11 nM (IC50)

FLT3

4 nM (IC50)

FLT1

39 nM (IC50)

ABL1 (T315I)

3 nM (IC50)

ABL1

6.8 nM (IC50)

SGK

67 nM (IC50)

SGK1

201 nM (IC50)

AurA

108 nM (IC50)

AurB

123 nM (IC50)

AurC

290 nM (IC50)

IKKβ

257 nM (IC50)

IKKα

591 nM (IC50)

TNFα

460 nM (IC50)

ROCK1

1030 nM (IC50)

ROCK2

111 nM (IC50)

CDK1

1125 nM (IC50)

CDK2

1180 nM (IC50)

TRKA

85 nM (IC50)

c-MET

177 nM (IC50)

TRKB

217 nM (IC50)

IGF1R

307 nM (IC50)

LCK

333 nM (IC50)

MEKK2

661 nM (IC50)

SYK

731 nM (IC50)

AMPK

1512 nM (IC50)

JNK1

3280 nM (IC50)

SRC

4330 nM (IC50)

ZAP70

5050 nM (IC50)

ERK2

6290 nM (IC50)

P38α

12050 nM (IC50)

CYP3A4

16.2 μM (IC50)

体外研究
(In Vitro)

The effect of URMC-099 (URMC099) on the in vitro growth of the “brain homing” MDA-MB-231 BR cells expressing eGFP (eGFP8.4) and their parental cell line, MDA-MB-231 is tested. The cells are treated with either 200 nM URMC-099 or vehicle alone. Cells treated with URMC-099 grow at a similar rate to those treated with vehicle. Cell viability is >99% in all cases[2].

体内研究
(In Vivo)

URMC-099 has moderate terminal elimination half-life (t1/2=1.92 h, 2.14 h and 2.72 h for C57 BL/6 mice (10 mg/kg, oral dosing), C57 BL/6 mice (2.5 mg/kg, iv), C57 BL/6 mice (10 mg/kg, iv))[1]. The effect of URMC-099 (URMC099) on tumor formation in vivo is analyzed using a well characterized mouse xenograft model of breast cancer brain metastasis. For these experiments, eGFP8.4 cells are inoculated into the left ventricle of immunodeficientnu/numice; animals are then treated with either URMC-099 (10 mg/kg) or vehicle alone, every 12 hours for 20 days. This dose of URMC-099 is chosen because it has been shown to be sufficient to effectively inhibit MLK3 in mice, with good penetration of the blood-brain barrier and potent inhibition of the phosphorylation of Jun N-terminal kinase (JNK) in brain tissue. On day 21 the mice are sacrificed and number of BM is assessed. Fifteen mice are used for each treatment group. BM are detected in 60% of mice, which is consistent with previous studies using this xenograft model by other investigators. URMC-099 treatment significantly (p<0.05, two-tailed t-test) increases the total number of brain metastasis (BM) in mice. For micrometastases, the pattern is similar to that observed for total BM. The number of macrometastases is statistically indistinguishable between mice treated with URMC-099 or vehicle[2].

分子量

421.54

性状

Solid

Formula

C27H27N5

CAS 号

1229582-33-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : ≥ 33 mg/mL(78.28 mM)

*"≥" means soluble, but saturation unknown.

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.3723 mL11.8613 mL23.7225 mL
5 mM0.4745 mL2.3723 mL4.7445 mL
10 mM0.2372 mL1.1861 mL2.3723 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 5% DMSO    40%PEG300   5%Tween-80   50% saline

    Solubility: ≥ 2.87 mg/mL (6.81 mM); Clear solution

  • 2.

    请依序添加每种溶剂: 5% DMSO    95% (20%SBE-β-CDin saline)

    Solubility: ≥ 2.87 mg/mL (6.81 mM); Clear solution

  • 3.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.08 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
  • 4.

    请依序添加每种溶剂: 10% DMSO    90% (20%SBE-β-CDin saline)

    Solubility: ≥ 2.08 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.93 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 5.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 2.08 mg/mL (4.93 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.93 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。